Corrigendum to “Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine” [Vaccine 62 (2025) 127558]

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2025-10-08 DOI:10.1016/j.vaccine.2025.127785

Tarek El Hindi , Suvaporn Anugulruengkitt , Keswadee Lapphra , Kriengsak Limkittikul , Auchara Tangsathapornpong , Claudia M. Galindo , Michael Hellwig , Nicholas Roubinis , Ron Schuring , Shibadas Biswal , Nicolas Folschweiller

引用次数: 0

查看原文本刊更多论文

“与重组9价人乳头瘤病毒疫苗联合使用的四价登革热减毒活疫苗（TAK-003）的免疫原性和安全性”[疫苗62(2025)127558]的勘误

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.